Anti-SEMA4B monoclonal antibody

Pre-made anti-SEMA4B monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to SEMA4B/SEMA4B products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1605-Ab-1/ GM-Tg-hg-IP1605-Ab-2Anti-Human SEMA4B monoclonal antibodyHuman
GM-Tg-rg-IP1605-Ab-1/ GM-Tg-rg-IP1605-Ab-2Anti-Rat SEMA4B monoclonal antibodyRat
GM-Tg-mg-IP1605-Ab-1/ GM-Tg-mg-IP1605-Ab-2Anti-Mouse SEMA4B monoclonal antibodyMouse
GM-Tg-cynog-IP1605-Ab-1/ GM-Tg-cynog-IP1605-Ab-2Anti-Cynomolgus/ Rhesus macaque SEMA4B monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1605-Ab-1/ GM-Tg-felg-IP1605-Ab-2Anti-Feline SEMA4B monoclonal antibodyFeline
GM-Tg-cang-IP1605-Ab-1/ GM-Tg-cang-IP1605-Ab-2Anti-Canine SEMA4B monoclonal antibodyCanine
GM-Tg-bovg-IP1605-Ab-1/ GM-Tg-bovg-IP1605-Ab-2Anti-Bovine SEMA4B monoclonal antibodyBovine
GM-Tg-equg-IP1605-Ab-1/ GM-Tg-equg-IP1605-Ab-2Anti-Equine SEMA4B monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1605-Ab-1/ GM-Tg-hg-IP1605-Ab-2; GM-Tg-rg-IP1605-Ab-1/ GM-Tg-rg-IP1605-Ab-2;
GM-Tg-mg-IP1605-Ab-1/ GM-Tg-mg-IP1605-Ab-2; GM-Tg-cynog-IP1605-Ab-1/ GM-Tg-cynog-IP1605-Ab-2;
GM-Tg-felg-IP1605-Ab-1/ GM-Tg-felg-IP1605-Ab-2; GM-Tg-cang-IP1605-Ab-1/ GM-Tg-cang-IP1605-Ab-2;
GM-Tg-bovg-IP1605-Ab-1/ GM-Tg-bovg-IP1605-Ab-2; GM-Tg-equg-IP1605-Ab-1/ GM-Tg-equg-IP1605-Ab-2
Products NameAnti-SEMA4B monoclonal antibody
Formatmab
Target NameSEMA4B
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-SEMA4B monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1605-Ag-1Recombinant multi-species SEM4B/ SEMA4B/ SEMAC protein


    Target information

    Target IDGM-IP1605
    Target NameSEMA4B
    Gene ID10509,20352,293042,708168,488741,101089108,510140,100069054
    Gene Symbol and SynonymsmKIAA1745,sema C,SEMA4B,SEMAC,SemC
    Uniprot AccessionQ9NPR2
    Uniprot Entry NameSEM4B_HUMAN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000185033
    Target ClassificationN/A

    The target: SEMA4B, gene name: SEMA4B, also named as SEMAC, SemC. Predicted to enable chemorepellent activity and semaphorin receptor binding activity. Predicted to be involved in several processes, including generation of neurons; neural crest cell migration; and semaphorin-plexin signaling pathway. Predicted to be located in plasma membrane. Predicted to be active in extracellular space. Predicted to be integral component of plasma membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.